The Non-Hodgkin's Lymphoma Drug Market Will Nearly Double to More Than ... Sacramento Bee The Pharmacor advisory service entitled Non-Hodgkin's Lymphoma finds that sales of rituximab dominate the current market, and will continue to do so through 2022, regardless of biosimilar rituximab entry. Teva Pharmaceutical Industries' ... |
